Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 11/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 11/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455476 | 0.93 | AKT1 (0.44) | AKT1ABL1AKT2AKT3GSK3B | |
| SCHEMBL31455042 | 0.93 | AKT1 (0.44) | AKT1ABL1AKT2AKT3GSK3B | |
| SCHEMBL31455477 | 0.86 | AKT1 (0.46) | AKT1ABL1AKT2AKT3GSK3B | |
| SCHEMBL31455265 | 0.79 | AKT1 (0.45) | AKT1ABL1AKT2AKT3GSK3B | |
| SCHEMBL31455097 | 0.78 | AKT1 (0.55) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455278 | 0.78 | AKT1 (0.51) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455166 | 0.77 | AKT1 (0.50) | AKT1ABL1AKT2AKT3GSK3B | |
| SCHEMBL31455221 | 0.74 | AKT1 (0.43) | AKT1AKT2AKT3CYP2C9 | |
| SCHEMBL31455271 | 0.74 | AKT1 (0.59) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455139 | 0.74 | AKT1 (0.50) | AKT1ABL1AKT2AKT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |